[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100315170":3},{"organization":4,"armGroups":7,"interventions":54,"overallOfficials":103,"centralContacts":103,"locations":104,"responsibleParty":117,"collaborators":103,"id":119,"slug":120,"hasResults":121,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":103,"eligibilityCriteria":125,"healthyVolunteers":126,"sex":127,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":103,"studyType":133,"phases":134,"briefSummary":136,"conditions":137,"keywords":103,"overallStatus":139,"whyStopped":103,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":148},{"fullName":5,"class":6},"Jeil Pharmaceutical Co., Ltd.","INDUSTRY",[8,14,19,24,29,34,39,44,49],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","Single-ascending cohort 1",[13],"Drug: Cohort 1 (JP-1366 A mg)",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","Single-ascending cohort 2",[18],"Drug: Cohort 2 (JP-1366 B mg)",{"label":20,"type":10,"description":21,"interventionNames":22},"Cohort 3","Single-ascending cohort 3",[23],"Drug: Cohort 3 (JP-1366 C mg)",{"label":25,"type":10,"description":26,"interventionNames":27},"Cohort 4","Single-ascending cohort 4",[28],"Drug: Cohort 4 (JP-1366 D mg)",{"label":30,"type":10,"description":31,"interventionNames":32},"Cohort 5","Single-ascending cohort 5",[33],"Drug: Cohort 5 (JP-1366 E mg)",{"label":35,"type":10,"description":36,"interventionNames":37},"Cohort 6","Multiple-ascending cohort 1",[38],"Drug: Cohort 6 (JP-1366 F mg)",{"label":40,"type":10,"description":41,"interventionNames":42},"Cohort 7","Multiple-ascending cohort 2",[43],"Drug: Cohort 7 (JP-1366 G mg)",{"label":45,"type":10,"description":46,"interventionNames":47},"Cohort 8","Multiple-ascending cohort 3",[48],"Drug: Cohort 8 (JP-1366 H mg)",{"label":50,"type":10,"description":51,"interventionNames":52},"Cohort 9","Multiple-ascending cohort 4",[53],"Drug: Cohort 9 (JP-1366 I mg)",[55,62,67,72,77,82,88,93,98],{"type":56,"name":57,"description":58,"armGroupLabels":59,"otherNames":60},"DRUG","Cohort 1 (JP-1366 A mg)","Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg",[9],[61],"SAD",{"type":56,"name":63,"description":64,"armGroupLabels":65,"otherNames":66},"Cohort 2 (JP-1366 B mg)","Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg",[15],[61],{"type":56,"name":68,"description":69,"armGroupLabels":70,"otherNames":71},"Cohort 3 (JP-1366 C mg)","Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg",[20],[61],{"type":56,"name":73,"description":74,"armGroupLabels":75,"otherNames":76},"Cohort 4 (JP-1366 D mg)","Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg",[25],[61],{"type":56,"name":78,"description":79,"armGroupLabels":80,"otherNames":81},"Cohort 5 (JP-1366 E mg)","Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg",[30],[61],{"type":56,"name":83,"description":84,"armGroupLabels":85,"otherNames":86},"Cohort 6 (JP-1366 F mg)","Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg",[35],[87],"MAD",{"type":56,"name":89,"description":90,"armGroupLabels":91,"otherNames":92},"Cohort 7 (JP-1366 G mg)","Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg",[40],[87],{"type":56,"name":94,"description":95,"armGroupLabels":96,"otherNames":97},"Cohort 8 (JP-1366 H mg)","Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg",[45],[87],{"type":56,"name":99,"description":100,"armGroupLabels":101,"otherNames":102},"Cohort 9 (JP-1366 I mg)","Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg",[50],[87],null,[105],{"facility":106,"status":103,"city":107,"state":108,"zip":109,"country":110,"countryCode":103,"cosmosGeoPoint":111,"geoPoint":116,"contacts":103},"Seoul National University Hospital(SNUH)","Seoul","Jongno-Gu","110-744","South Korea",{"type":112,"coordinates":113},"Point",[114,115],126.9784,37.566,{"lat":115,"lon":114},{"type":118,"investigatorFullName":103,"investigatorTitle":103,"investigatorAffiliation":103,"oldNameTitle":103,"oldOrganization":103},"SPONSOR","100315170","phase-1-clinical-trial-to-investigate-the-safety-tolerability-and-pharmacokinetics-and-pharmacodynamics-of-jp-1366-oral-administration-in-healthy-male-subjects-100315170",false,"NCT03383042","Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects","A Randomized, Open-label, Placebo- and Active- Controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects","Inclusion Criteria:\n\n* Healthy adult males aged between 19 and 50 at screening\n* Weight is between 55 and 90 kg and BMI is between 18.0 and 27.0\n* Those who are adequate to be subjects in this study upon judgment of the investigator after physical examination, clinical laboratory test, examination by interview, etc\n\nExclusion Criteria:\n\n* Subject has clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history\n* Subject has gastrointestinal diseases or past history of gastrointestinal diseases (gastrointestinal ulcer, gastritis, gastrospasm, gastroesophageal reflux, Crohn's disease etc.) that may affect safety and pharmacokinetic\u002Fpharmacodynamic evaluation of study drug, and those who have past history of gastrointestinal surgery (however, except simple appendectomy and herniotomy)\n* Subject has been Helicobacter pylori positive\n* AST (SGOT) and ALT (SGPT) \\> 1.5 times to the upper limit of the normal range in screening including additional examinations prior to randomization\n* Subject has anatomical disability in insertion and maintenance of pH meter catheter",true,"MALE","19 Years","50 Years",{"count":131,"type":132},115,"ACTUAL","INTERVENTIONAL",[135],"PHASE1","Clinical trial to investigate the safety, tolerability and pharmacokinetics and pharmacodynamics of JP-1366 oral administration in healthy male subjects",[138],"Anti-Ulcer Agents","COMPLETED","2019-04-18",{"date":142,"type":132},"2019-04-22",{"date":144,"type":132},"2017-12-22",{"date":146,"type":132},"2019-04-05",{"name":5,"class":6},1]